Fast Locator 2014-2015: Lyophilization - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Fast Locator 2014-2015: Lyophilization


Lyophilization Technology, Inc.
30 Indian Drive
Ivyland, PA 18974
Phone: +1 215-396-8373
Fax: +1 215-396-8375
Email: inquiry@lyo-t.com

Regions served:
Asia, North America, Europe

Description:
Lyophilization Technology, Inc. (LTI) was formed in 1992 to provide an extensive range of scientific services and technical support in freezing and freeze drying.  As a Contract Development and Manufacturing Organization (CDMO), our services range from product and process development and integration of a new product and process into commercial manufacturing operations through clinical trial material preparation.  With our expertise and flexibility, you realize the benefits from development, clinical material manufacturing, technical support, consulting services, and improved quality, efficiency, and compliance for new and commercial lyophilized products.

LTI is a Contract Development and Manufacturing Organization focused on all aspects of Lyophilization.  A talented and dedicated staff, skilled through experience, is coupled with in-house capabilities in product development, process engineering, clinical manufacturing, and technical support.  Recognized as an industry leader, the company has a proven reputation in providing innovative solutions, achieving desired results, and exceeding client expectations.

Experience with a wide variety of products, including small molecules, cytotoxics, biologics, highly potent compounds, vaccines, medical devices and diagnostic agents, LTI has successfully developed formulations, designed manufacturing processes, and prepared material for clinical trials. Gain the benefits of LTI’s experience and capabilities for creating solutions for the unique needs of your lyophilized products.

Website:
www.lyotechnology.com

Services Provided:
Development Sciences

  • Low temperature thermal analysis
  • Product design
  • Formulation development
  • Cycle design/refinement
  • Lyophilized/liquid filling in vials, cartridges, or other custom container closures
  • Product characterization
  • Praxair® ControLyo™ controlled nucleation technology
  • Isolation/containment
  • Pilot plant scale-up
  • Toxicology material
  • Technical transfer to commercial manufacturing

Clinical Manufacturing

  • Pre-clinical to Phase II clinical materials, lyophilized, and liquid products
  • Sterile toxicology material processing
  • Aseptic vial filling
  • Aseptic cartridge filling
  • Small-batch manufacturing
  • Specialized, flexible capabilities
  • Praxair® ControLyo™ controlled nucleation technology

Technical Services

  • Product, process, and/or cycle evaluation
  • On-site/in-house training
  • Equipment IQ/OQ
  • Consulting and auditing
  • Troubleshooting
  • Equipment/specifications
  • Quality/compliance support

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications

Click here